Advertisement

Amantadin

  • J. Kornhuber
  • J. Wiltfang
  • M. Streifler

Zusammenfassung

Seit der ersten Ausgabe der „Neuro-Psycho-pharmaka“ sind viele neue präklinische Befunde zu Amantadin erhoben worden. Amantadin gehÖrt zur Gruppe der Adamantanamine. Diese Substanzen bestehen aus einer polaren Aminogruppe und dem apolaren Kohlenwasserstoffskelett des Adamantans, welches aus vier gleichartigen, in der Sesselform fixierten Sechsringen besteht (Abb. 7.1.1). Der Name „Adamantan“ leitet sich von „Diamant“ ab und nimmt damit bezug auf die strukturelle Ähnlichkeit der KohlenwasserstoffgerÜste. Die Erstsynthese von Amantadin wurde 1960 beschrieben (Stetter et al. 1960). Wenig später wurde die antivirale Aktivität von Amantadin bekannt (Davies et al. 1964), und 1968 beobachtete eine Patientin unter der Grippeprophylaxe mit Amantadin eine Besserung ihrer Parkinson-Symptomatik (Schwab et al. 1969). Dieser Zufallsbefund konnte bald durch systematische Untersuchungen bestätigt werden (Parkes et al. 1970).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anonymous (1996) Morbus Parkinson. Vigilanz-und AntriebsstÖrungen. Merz + Co, Frankfurt am MainGoogle Scholar
  2. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366–375PubMedGoogle Scholar
  3. Albuquerque EX, Eldefrawi AT, Eldefrawi ME, Mansour NA, Tsai M-C (1978) Amantadine: neuromuscular blockade by supression of ionic conductance of the acetylcholine receptor. Science 199: 788–790PubMedGoogle Scholar
  4. Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14: 35–51PubMedGoogle Scholar
  5. Aoki FY, Sitar DS, Ogilvie RI (1979) Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther 26: 729–736PubMedGoogle Scholar
  6. Aronstam RS, Eldefrawi AT, Eldefrawi ME (1980) Similarities in the binding sites of the muscarinic receptor and the ionic channel of the nicotinic receptor. Biochem Pharmacol 29: 1311–1314PubMedGoogle Scholar
  7. Ashcroft FM, Kerr AJ, Gibson JS, Williams BA (1991) Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line. Br J Pharmacol 104: 579–584PubMedGoogle Scholar
  8. Bailey EV, Stone TW (1975) The mechanism of action of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn 216: 246–262PubMedGoogle Scholar
  9. Bleidner WE, Harmon JB, Hewes WK, Lynes TE, Hermann EC (1965) Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 150: 484–490PubMedGoogle Scholar
  10. Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H (1997) Amantadine and human borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349: 178–179PubMedGoogle Scholar
  11. Bowman MA, Kirk JK, Michielutte R, Preisser JS (1997) Use of amantadine for chronic fatigue syndrome. Arch Intern Med 157: 1264–1265PubMedGoogle Scholar
  12. Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236: 153–156PubMedGoogle Scholar
  13. Brown F, Redfern PH (1976) Studies on the mechanism of action of amantadine. Br J Pharmacol 58: 561–567PubMedGoogle Scholar
  14. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine depleted mice. J Neural Transm 75: 221–226PubMedGoogle Scholar
  15. Cha J-HJ, Durel VLS, Sakurai SY, Penney JB, Young AB (1991) 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces PHIAMPA binding in rat striatum. Neurosci Lett 132: 55–58PubMedGoogle Scholar
  16. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436PubMedGoogle Scholar
  17. Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46: 676–680PubMedGoogle Scholar
  18. Colman RW, Kuchibhotla J, Jain MK, Murray RK (1977) Phase separation in phosphatidylcholine bilayers as a predictor of inhibition of blood platelet aggregation by amantadines. Biochem Biophys Acta 467: 273–279PubMedGoogle Scholar
  19. Cook PE, Dermer SW, Mcgurk T (1986) Fatal overdose with amantadine. Can J Psychiatry 31: 757–758PubMedGoogle Scholar
  20. Costall B, Naylor RJ (1975) Neuropharmacological studies on D145. Psychopharmacologia 43: 53–61PubMedGoogle Scholar
  21. Danysz W, Essmann U, Bresink I, Wilke R (1994a) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48: 111–118PubMedGoogle Scholar
  22. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994b) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? — Case of amantadine and memantine. J Neural Transm [PD Sect] 7: 155–166Google Scholar
  23. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies. Neurosci Biobehav Rev 21: 455–468PubMedGoogle Scholar
  24. Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144: 862–863PubMedGoogle Scholar
  25. Dichiara G, Morelli M, Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17: 228–233Google Scholar
  26. Dimascio A, Bernardo DL, Greenblatt DJ, Marder JE (1976) A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33: 599–602PubMedGoogle Scholar
  27. Dunn JP, Henkel JG, Gianutsos G (1986) Pharmacological activity of amantadine: effect of N-alkyl substitution. J Pharm Pharmacol 38: 353–356PubMedGoogle Scholar
  28. Eletr S, Williams MA, Watkins T, Keith AD (1974) Perturbations of the dynamics of lipid alkyl chains in membrane systems: effect on the activity of membrane-bound enzymes. Biochem Biophys Acta 339: 190–201Google Scholar
  29. Farnebo LO, Fuxe K, Goldstein M, Manberg B, Ungerstedt U (1971) Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson’s disease. Eur J Pharmacol 16: 27–38PubMedGoogle Scholar
  30. Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 110: 357–361PubMedGoogle Scholar
  31. Greenamyre JT, O’Brien CF (1991) N-Methyl-D-aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48: 977–981PubMedGoogle Scholar
  32. Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 4: 258–270Google Scholar
  33. Hayden FG, Hall WJ, Douglas RG, Speers DM (1979) Amantadine aerosols in normal volunteers: pharmacology and safety testing. Antimicrob Agents Chemother 16: 644–650PubMedGoogle Scholar
  34. Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for 3H-dopamine in rat brain slices. Eur J Pharmacol 20: 156–160PubMedGoogle Scholar
  35. Henkel JG, Hane JT (1982) Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem 25: 51–56PubMedGoogle Scholar
  36. Horadam VW, Sharp JG, Smilack JD, Mcanalley BH, Garriott JC, Stephens MK, Prati RC, Brater DC (1981) Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Int Med 94: 454–458PubMedGoogle Scholar
  37. Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320: 21–42PubMedGoogle Scholar
  38. Janiec W, Piekarska T, Szczypior M, Misterkiewicz E (1977) The effect of apomorphine, amantadine and dimethylaminoadamantane on the level of cyclic AMP in the rat striatum. Pol J Pharmacol Pharm 29: 93–99PubMedGoogle Scholar
  39. Janiec W, Piekarska T, Paletko Z, Pytlik M (1978) The effect of drugs stimulating central dopaminergic system on transformation of exogenous adenine into cAMP. Pol J Pharmacol Pharm 30: 529–535PubMedGoogle Scholar
  40. Karobath ME (1974) Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenylate cyclase from the caudate-putamen of the rat brain. Eur J Pharmacol 28: 376–378PubMedGoogle Scholar
  41. Kelly JT, Zimmerman RL, Abuzzahab FS, Schiele BC (1974) A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced Parkinsonism. Pharmacology 12: 65–73PubMedGoogle Scholar
  42. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson’s disease. Trends Neurosci 12: 285–286PubMedGoogle Scholar
  43. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539–546PubMedGoogle Scholar
  44. Klockgether T, Turski L (1993) Towards understanding of the role of glutamate in experimental Parkinsonism: agonist sensitive sites in the basal ganglia. Ann Neurol 34: 585–593PubMedGoogle Scholar
  45. Knight V, Bloom K, Wilson SZ, Wilson RK (1979) Amantadine aerosol in humans. Antimicrob Agents Chemother 16: 572–578PubMedGoogle Scholar
  46. König P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H (1996) Amantadine versus biperiden: a double-blind study of treatment-efficacy in neuroleptic EPS. Neuropsychobiology 33: 80–84PubMedGoogle Scholar
  47. Koppel C, Tenczer J (1985) A revision of the metabolic disposition of amantadine. Biomed Mass Spectrometry 12: 499–501Google Scholar
  48. Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357PubMedGoogle Scholar
  49. Kornhuber J, Weller M (1996) Neue therapeutische MÖglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten. Nervenarzt 67: 77–82PubMedGoogle Scholar
  50. Kornhuber J, Weller M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144PubMedGoogle Scholar
  51. Kornhuber J, Bormann J, Retz W, HÜBers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590PubMedGoogle Scholar
  52. Kornhuber J, Bormann J, HÜBers M, Rusche K, Riederer P (1991) Effects of the 1-amino-ada-mantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300Google Scholar
  53. Kornhuber J, Schoppmeyer K, Riederer P (1993a) Affinity of 1-aminoadamantanes for the a binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129–131PubMedGoogle Scholar
  54. Kornhuber J, Weller M, Riederer P (1993b) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neural Transm [PD Sect] 6: 63–72Google Scholar
  55. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104Google Scholar
  56. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995a) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713–721PubMedGoogle Scholar
  57. Kornhuber J, Retz W, Riederer P (1995b) Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm [Suppl] 46: 311–319Google Scholar
  58. Kraus MF, Maki P (1997a) The combined use of amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 11: 455–460PubMedGoogle Scholar
  59. Kraus MF, Maki PM (1997b) Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 9: 222–230PubMedGoogle Scholar
  60. Kroemer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, Kornhuber J (1998) Quantitative analysis of the structural requirements for blockade of the NMDA receptor at the PCP binding site. J Med Chem 41: 393–400PubMedGoogle Scholar
  61. Lampe H, Bigalke H (1991) Modulation of glycine-activated membrane current by adamantane derivatives. NeuroReport 2: 373–376PubMedGoogle Scholar
  62. Lassen JB (1973) The effect of amantadine and (+)-amphetamine on motility in rats after inhibition of monoamine synthesis and storage. Psychopharmacologia 29: 55–64PubMedGoogle Scholar
  63. Liu P, Cheng PJ, Ing TS, Daugirdas JT, Jeevanandhan R, Soung LS, Galinis S (1984) In vitro binding of amantadine to plasma proteins. Clin Neuropharmacol 7: 149–151PubMedGoogle Scholar
  64. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717–724PubMedGoogle Scholar
  65. Lustig HS, Ahern KB, Greenberg DA (1992) Antiparkinsonian drugs and in vitro excitotoxicity. Brain Res 597: 148–150PubMedGoogle Scholar
  66. Maj J (1982) Die Wirkung von Memantin auf zentrale Neurotransmittersysteme. Arzneimittelforschung/Drug Res 32: 1256–1259Google Scholar
  67. Maj J, Sowinska H, Baran L (1972) The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia 24: 296–307PubMedGoogle Scholar
  68. Maj J, Sowinska H, Baran L, Sarnek J (1974) Pharmacological effects of l,3-dimethyl-5-amino-adamantane, a new adamantane derivative. Eur J Pharmacol 26: 9–14PubMedGoogle Scholar
  69. Matsubayashi H, Swanson KL, Albuquerque EX (1997) Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281: 834–844PubMedGoogle Scholar
  70. Menon MK, Clark WG (1978) Pharmacological evidence for the involvement of GABA-ergic system in the locomotor stimulation produced in mice by l,3-dimethyl-5-aminoada-mantane (D-145). Neuropharmacology 17: 1049–1052PubMedGoogle Scholar
  71. Menon MK, Clark WG (1979) GABA-ergic drugs block the locomotor stimulant effects of 1,3-dimethyl-5-aminoadamantane (D-145). Neuropharmacology 18: 223–225PubMedGoogle Scholar
  72. Menon MK, Vivonia CA, Haddox VG (1984) Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants. Psychopharmacology Berl 82: 89–92PubMedGoogle Scholar
  73. Mizuno Y, Mori H, Kondo T (1994) Potential of neuroprotective therapy in Parkinsons disease. CNS Drugs 1: 45–56Google Scholar
  74. Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72: 394–397PubMedGoogle Scholar
  75. Müller T, Kuhn W, Quack G, Przuntek H (1995) Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. J Neural Transm 46: 407–413Google Scholar
  76. Northoff G, Eckert J, Fritze J (1997) Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMD A antagonist amantadine. J Neurol Neurosurg Psychiatry 62: 404–406PubMedGoogle Scholar
  77. Olney JW, Price MT, Labruyere J, Salles KS, Friedrich G, Mueller M, Silverman E (1987) Anti-parkinsonian agents are phencyclidine agonists and N-methyl-D-aspartate antagonists. Eur J Pharmacol 142: 319–320PubMedGoogle Scholar
  78. Ossowska K (1994) The role of excitatory amino acids in experimental models of Parkinson’s disease. J Neural Transm [PD-Sect] 8: 39–71Google Scholar
  79. Papeschi R (1974) Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology 13: 77–83PubMedGoogle Scholar
  80. Parkes D (1974) Amantadine. In: Harper NJ, Simmonds AB (eds) Advances in drug research. Academic Press, London, pp 11–81Google Scholar
  81. Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262Google Scholar
  82. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258PubMedGoogle Scholar
  83. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8:446–454PubMedGoogle Scholar
  84. Perrin DD, Hawkins I (1972) Dissociation constant of the 1-aminoadamantane cation. Experientia 28: 880Google Scholar
  85. Raffa RB, Ortegón ME, Robisch DM, Martin GE (1989) In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci 44: 1593–1599PubMedGoogle Scholar
  86. Rausch WD, Schallauer E, Chan WW, Riederer P, Weiser M (1990) Effects of L-deprenyl and amantadine in an MPTP-model of Parkinsonism. J Neural Transm [Suppl 32]: 269–275Google Scholar
  87. Reiser G, Koch R (1989) Memantine inhibits serotonin-induced rise of cytosolic Ca2+ activity and of cytosolic GMP level in a neuronal cell line. Eur J Pharmacol Mol Pharmacol Sect 172: 199–203Google Scholar
  88. Reiser G, Binmöller F-J, Koch R (1988) Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 443: 338–344PubMedGoogle Scholar
  89. Rizzo M, Biandrate P, Tognoni G, Morselli PL (1973) Amantadine in depression: relationship between behavioural effects and plasma levels. Eur J Clin Pharmacol 5: 226–228Google Scholar
  90. Rojas P, Altagracia M, Kravsov J, Rios C (1992) Partially protective effect of amantadine in the MPTP model of Parkinson’s disease. Proc West Pharmacol Soc 35: 33–35PubMedGoogle Scholar
  91. Rosenberg GA, Appenzeller O (1988) Amantadine, fatigue, and multiple sclerosis. Arch Neurol 45: 1104–1106PubMedGoogle Scholar
  92. Schmidt WJ, Bubser M (1989) Anti-cataleptic effects of the N-methyl-aspartate antagonist MK-801. Pharmacol Biochem Behav 32: 621–623PubMedGoogle Scholar
  93. Schmidt WJ, Bubser M, Hauber W (1990) Excitatory amino acids and Parkinson’s disease. Trends Neurosci 13: 46–47PubMedGoogle Scholar
  94. Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm [Suppl] 38: 65–89Google Scholar
  95. Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208: 1168–1170PubMedGoogle Scholar
  96. Silver H, Geraisy N, Schwartz M (1995) No difference in the effect of biperiden and amantadine on Parkinsonian — and tardive dyskinesia — type involuntary movements: a double blind crossover, placebo-controlled study in medicated chronic schizophrenic patients [published erratum J Clin Psychiatry 56 (1995) 435]. J Clin Psychiatry 56: 167–170Google Scholar
  97. Simpson DM, Ramos F, Ramirez LF (1988) Death of a psychiatric patient from amantadine poisoning. Am J Psychiatry 145: 267–268PubMedGoogle Scholar
  98. Skuza G, Rogoz Z, Quack G, Danysz W (1994) Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoaminedepleted rats. J Neural Transm [Gen Sect] 98: 57–67Google Scholar
  99. Sonsalla PK, Nicklas WJ, Heikkila RE (1989) Role of excitatory amino acids in methampheta-mine-induced nigrostriatal dopaminergic toxicity. Science 343: 398–400Google Scholar
  100. Soung L-S, Ing TS, Daugirdas JT, Wu M-J, Gandhi VC, Ivanovich PT, Hano JE, Viol GW (1980) Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med 93: 46–49PubMedGoogle Scholar
  101. Spector R (1988) Transport of amantadine and rimantadine through the blood-brain barrier. J Pharmacol Exp Ther 244: 516–519PubMedGoogle Scholar
  102. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson’s disease. Synapse 19: 264–293PubMedGoogle Scholar
  103. Stetter H, Mayer J, Schwarz M, Wulff K (1960) Beiträge zur Chemie der Adamantyl-(1)-Derivate. Chem Ber 93: 226–230Google Scholar
  104. Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439–443PubMedGoogle Scholar
  105. Svensson TH (1973) Dopamine release and direct dopamine receptor activation in the central nervous system by D-145, an amantadine derivative. Eur J Pharmacol 23: 232–238PubMedGoogle Scholar
  106. Tilley JW, Kramer MJ (1981) Aminoadamantane derivates. Progr Med Chem 18: 1–44Google Scholar
  107. Turski L, Bressler K, Rettig K-J, Löschmann P-A, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414–418PubMedGoogle Scholar
  108. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46: 1551–1556PubMedGoogle Scholar
  109. Vale S, Espejel MA, Dominguez JC (1971) Amantadine in depression. Lancet ii: 437Google Scholar
  110. Weller M, Kornhuber J (1992) Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63: 645–655PubMedGoogle Scholar
  111. Weller M, Finiels-Marlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613: 143–148PubMedGoogle Scholar
  112. Wenk GL, Danysz W, Mobley SL (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magno-cellularis. Eur J Pharmacol 293: 267–270PubMedGoogle Scholar
  113. Wesemann W (1983) Adamantanamine — neurobiologische Untersuchungen zur klinischen Wirkung einer polizyklischen Verbindungsklasse mit diamantähnlicher Struktur. Funkt Biol Med 2: 137–145Google Scholar
  114. Wesemann W, Ekenna O (1982) Effect of 1-amino-adamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelfor-schung/Drug Res 32: 1241–1243Google Scholar
  115. Wesemann W, Schollmeyer JD, Sturm G (1977) Gaschromatographische und massenspektro-metrische Untersuchungen über harnpflichtige Metabolite von Adamantanaminen. Arzneimittelf orschung/Drug Res 27: 1471–1477Google Scholar
  116. Wesemann W, Dette-Wildenhahn G, Fellehner H (1979) In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J Neural Transm 44: 263–285PubMedGoogle Scholar
  117. Wesemann W, Sturm G, Fünfgeld EW (1980) Distribution and metabolism of the potential anti-parkinson drug memantine in the human. J Neural Transm [Suppl] 16: 143–146Google Scholar
  118. Wesemann W, Sontag K-H, Maj J (1983) Zur Pharmakodynamik und Pharmakokinetik des Memantin. Arzneimittelforschung/Drug Res 33: 1122–1134Google Scholar

Literatur

  1. Alterman AJ, Droba M, Antelo RE, Cornish JW, Sweeney KR, Parikh CA, O’Brian CP (1992) Amantadine may facilitate detoxification of cocaine addicts. Drug-Alcohol Depend 31: 19–29PubMedGoogle Scholar
  2. Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler FunktionsstÖrungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblindstudie. Pharmacopsychiatry 21: 144–146PubMedGoogle Scholar
  3. Amdurski S, Radwan M, Levi A, Elizur A (1983) A therapeutic trial of amantadine in haloperidol-induced malignant neuroleptic syndrome. Curr Ther Res 33: 225–229Google Scholar
  4. Aoki FY, Sitar DS (1985) Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 37: 137–144PubMedGoogle Scholar
  5. Appleton DB, Eadie MJ, Sutherland JM (1970) Amantadine hydrochloride in the treatment of Parkinsonism: a controlled trial. Med J Aust 2: 626–629PubMedGoogle Scholar
  6. Baehr M, Eschweiler GW, Dichgans J (1994) Neuronal protection in neurological disease? Nervenarzt 65: 355–360Google Scholar
  7. Blanchard DL (1990) Amantadine caused corneal edema (letter). Cornea 9: 181PubMedGoogle Scholar
  8. Borman J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591–592Google Scholar
  9. Botez MJ, Young SN, Botez T, Pedraza OL (1991) Treatment of heredodegenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 18: 307–311PubMedGoogle Scholar
  10. Brenner M, Haas A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Partinson’s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 23: 153–156Google Scholar
  11. Chandler MC, Barnhill JJ, Gualtierei CT (1988) Amantadine for the agitated head injury patient. Brain Injury 2: 309–311PubMedGoogle Scholar
  12. Chen HS, Pellegrini JW, Aggarval SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine; therapeutic advantage against NMDA-receptor-mediated neurotoxity. J Neurosci 12: 4427–4436PubMedGoogle Scholar
  13. Chiba S, Ito M, Matsumoto H (1992) Amantadme treatment for refractory pain and fatigue in patients with multiple sclerosis. Can J Neurol Sci 19: 309PubMedGoogle Scholar
  14. Cohen RA, Fisher M (1989) Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 46: 676–680PubMedGoogle Scholar
  15. Cook PE, Dermer SW, Mcgurk T (1986) Fatal overdose with amantadine. Can J Psychiatry 31: 757–758PubMedGoogle Scholar
  16. Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Vortrag. Amantadin-Symposium, Bad NauheimGoogle Scholar
  17. Danielczyk W (1979a) MeditkamentÖs ausgelÖste Psychosen bei neurologisch erkrankten älteren Menschen. Akt Gerontol 9: 427–431Google Scholar
  18. Danielczyk W (1979b) Akute pharmakotoxische Psychosen bei chronischen zerebralen Erkrankungen. Wien Med Wochenschr 129[Suppl 55]: 1–15Google Scholar
  19. Danielczyk W (1995) Twenty-five years of amantadine therapy in Parkinson’s disease. J Neural Transm [Suppl] 46: 395–401Google Scholar
  20. Davies JR, Grilli EA, Smith AJ, Hoskins TW (1988) Prophylactic use of amantadine in a boarding school outbreak of influenza A. J Roy Coll Gen Pract 38: 346–348Google Scholar
  21. Delay J, Deniker P (1968) Drug induced extrapyramidal syndromes. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 6. Diseases of the basal ganglia. North Holland, Amsterdam, pp 248–266Google Scholar
  22. Drake ME Jr, Pakalnis A, Demo LS, Phillips B (1991) Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 91: 159–164PubMedGoogle Scholar
  23. Dunn MG (1991) Post-polio fatigue treated with amantadine. Arch Neurol 48: 570PubMedGoogle Scholar
  24. Erkulwaters S, Pillai R (1989) Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 82: 550–554Google Scholar
  25. Fahn S, Craddock G, Kumin G (1971) Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 25: 45–48PubMedGoogle Scholar
  26. Filla A, De-Michele G, Orefice G, Santorelli F, Trombetta L, Banfi S, Squitieri F, Napolitano G, Puma D, Campanella G (1993) A double cross-over trial of amantadine hydrochloride in Friedreich’s ataxia. Can J Neurol Sci 20: 52–55PubMedGoogle Scholar
  27. Fisher DA (1982) Recurrent herpes simplex sciatica and its treatment with amantadine hydrochloride. Cutis 29: 467–472PubMedGoogle Scholar
  28. Fraunfelder FT, Meyer SM (1990) Amantadine and corneal deposits. Am J Ophthalmol 110: 96–97PubMedGoogle Scholar
  29. Fünfgeld EW (1970) Amantadinwirkung bei Parkinsonismus. Dtsch Med Wochenschr 95: 1834–1836PubMedGoogle Scholar
  30. Fünfgeld EW (1972) Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther Woche 39: 3282–3299Google Scholar
  31. Fünfgeld EW (1985) Erfahrungen mit Memantin bei der Behandlung extrapyramidaler und pyramidaler BewegungsstÖrungen. Med Praxis 80: 3–7Google Scholar
  32. Galbraith AW (1983) Prevention of post-herpetic neuralgy by amantadine hydrochloride (Symmetrel). Br J Clin Pract 37: 304–306PubMedGoogle Scholar
  33. Greenamyre JT, O’Brian CF (1991) N-Methyl-D-Aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48: 977–981 (and comment in Arch Neurol [1992] 49: 900–901)PubMedGoogle Scholar
  34. Grossmann W, Schütz W (1982) Memantine und neurogene BlasenstÖrungen im Rahmen spastischer Zustandsbilder. Arzneimittelfor-schung/Drug Res 32: 1273–1276Google Scholar
  35. Hamburg P, Weilburg JB, Cassem NH, Cohen L, Brown S (1986) Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Compr Psychiatry 27: 272–275PubMedGoogle Scholar
  36. Horiguchi J, Inami Y, Shoda T (1990) Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 13: 84–86PubMedGoogle Scholar
  37. Jackson GG, Muldoon RL, Akers LW (1968) Serological evidence for prevention of influenza infection in volunteers by an antiinfluenzal drug: adamantanamin hydrochloride. Anti-microb Agents Chemother 3: 703–707Google Scholar
  38. Jörg J (1987) Therapie des Parkinsonsyndroms. Prakt Arzt 570: 1619–1622Google Scholar
  39. Kelly JT, Abuzzahab FS (1971) The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharm 11: 211–214Google Scholar
  40. Kemp BA, Gora ML (1993) Amantadine and fatigue of multiple sclerosis. Ann Pharmacother 27: 893–895PubMedGoogle Scholar
  41. Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm [PD-Sect] 6: 63–72Google Scholar
  42. Kornhuber J, Weller M (1993) Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm [Gen-Sect] 92: 57–65Google Scholar
  43. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS (1992) Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 49: 894–898PubMedGoogle Scholar
  44. Kugler J (1975) Influence of aminoamantadine sulphate on vigilance and awareness. Acta Neurol 2: 43–51Google Scholar
  45. Kunzelmann V (1993) Oral combination therapy of zoster neuralgia. Pain reduction by 1-aman-tadine sulfate and carbamazepine per os. Fort-schr Med 111: 423–425Google Scholar
  46. Lammers GJ, Roos BA (1993) Hyponatremia due to amantadine hydrochloride and L-dopa/car-bidopa (letter). Lancet 348: 439Google Scholar
  47. Leskow P (1987) Therapie zentral bedingter BewegungsstÖrungen. Multicenterstudie mit Memantine. Therapiewoche 37: 4843–4845Google Scholar
  48. Leskow P, Lachenmeyer L (1992) Parkinson therapy, yesterday, today, tomorrow. Neuroprotection gains in importance. Fortschr Med 110: 589–592PubMedGoogle Scholar
  49. Lieb W, May G (1972) On the treatment of herpetic keratitis with a new amantadine derivative. Klin Monatsbl Augenheilkd 161: 197–206PubMedGoogle Scholar
  50. Mcevoy JP (1987) A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 48 [Suppl]: 20–23PubMedGoogle Scholar
  51. Mcevoy JP, Mccue M, Freter S (1987) Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther 9: 429–433PubMedGoogle Scholar
  52. Merrick EM, Schmitt PP (1973) A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Curr Ther Res 15: 552–558PubMedGoogle Scholar
  53. Miller KS, Miller JM (1994) Toxic effects of amantadine in patients with renal failure (letter). Chest 105: 1630PubMedGoogle Scholar
  54. Miltner FO (1982) Wertigkeit der symptomatischen Therapie mit Memantine beim cerebralen Koma. I. Korrelation von Komastadien und EEG-Spektralverläufen. Arzneimittelfor-schung/Drug Res 32: 1268–1270Google Scholar
  55. Mitchell G (1993) Update on multiple sclerosis therapy. Med Clin North Am 77: 231–249PubMedGoogle Scholar
  56. Morgan MY (1991) The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 38: 377–387PubMedGoogle Scholar
  57. Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. J Pharmacol Toxicol 72: 394–397Google Scholar
  58. Mostow SR (1987) Prevention, management and control of influenza. Role of amantadine. Am J Med 82: 35–41Google Scholar
  59. Muller SR, Dastoor DP, Klinger A, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 27: 9–16PubMedGoogle Scholar
  60. Murray TJ (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12: 251–254PubMedGoogle Scholar
  61. Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT (1986) Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 143: 1170–1171PubMedGoogle Scholar
  62. Nickels JL, Schneider WN, Dombovy ML, Wong TM (1994) Clinical use of amantadine in brain injury rehabilitation. Brain Inj 8: 709–718PubMedGoogle Scholar
  63. Nogaki H, Morimatsu M (1993) Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride (letter). J Neurol 240: 388–389PubMedGoogle Scholar
  64. Ott L (1983) Klinische Beobachtungen und Erfahrungen mit Memantine bei spastischen BewegungsstÖrungen. Klinikarzt 12 [Suppl]: 19–20Google Scholar
  65. Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Marselli PL (1976) Effect of amantadine on drug-induced Parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 3: 883–889PubMedGoogle Scholar
  66. Pandit PB, Chytayat D, Jefferies AL, Landes A, Qamar IV, Koren G (1994) Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod Toxicol 8: 89–92PubMedGoogle Scholar
  67. Parkes JD, Zilka KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262Google Scholar
  68. Parkes JD (1971) Side-effects in Parkinson’s disease. A new approach to treatment. In: Birdwood GFB, Gilder SS, Wink CAS (eds). Academic Press, London New York, p 72Google Scholar
  69. Pellegrini JW, Lipton SA (1993) Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 33: 403–407PubMedGoogle Scholar
  70. Peterson PL, Saad J, Nigro MA (1988) The treatment of Friedreich’s ataxia with amantadine hydrochloride. Neurology 38:1478–1480PubMedGoogle Scholar
  71. Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMD A receptor antagonist, in the treatment of Parkinson’s disease. J Neural Transm 4: 277–282Google Scholar
  72. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelfor-schung/Drug Res 42: 256–268Google Scholar
  73. Robertson DR, George CF (1990) Treatment of post-herpetic neuralgia in the elderly. Br Med Bull 46: 113–123PubMedGoogle Scholar
  74. Roca RP, Santmyer R, Gloth FM, Denman SJ (1990) Improvements in activity and appetite among long-term care patients treated with amantadine. A clinical report. J Am Geriatr Soc 38: 675–677PubMedGoogle Scholar
  75. Rohde H (1982) Ergebnisse klinischer PrÜfungen des Antispastikums Memantine. Fortschr Med 43: 2023–2026Google Scholar
  76. Rojtman M, Apter E, Lahav S, Tiano S (1981) Amantadine in malignant neuroleptic syndrome (Hebrew with English Abstract). Harefuah 100: 333–334PubMedGoogle Scholar
  77. Rosa F (1994) Amantadine pregnancy experience (letter). Reprod Toxicol 8: 531PubMedGoogle Scholar
  78. Rosenberg GA, Appenzeller D (1988) Amantadine, fatigue and multiple sclerosis. Arch Neurol 45: 1104–1106PubMedGoogle Scholar
  79. Rumpf KW, Rummel J, Meinhold J, Clemens C (1990) Schwere Nebenwirkungen von Amantadin bei Niereninsuffizienz. Dtsch Ärztebl 87: 352Google Scholar
  80. Sandyk R, Jacono RP, Snider SR (1987) Amantadine for levodopa resistent parkinsonism. Int Neurosci 32: 715–717Google Scholar
  81. Schinitsy MR (1992) Reversal of neurologic deficits in Down syndrome. Am J Dis Child 146: 783PubMedGoogle Scholar
  82. Schubert H, König P, Schultes H, Havelec L (1995) Amatadine versus biperidin: a double-blind study of treatment efficacy in neuroleptic EPS. J Neural Transm [Gen Sect] 102: XLI (Abstract)Google Scholar
  83. Schwab RS, England Jr AC, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1163–1170Google Scholar
  84. Sears SD, Clements ML (1987) Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 31: 1470–1473PubMedGoogle Scholar
  85. Segal AW (1985) Variations on the theme of chronic granulomatous disease. Lancet i: 1378–1383Google Scholar
  86. Shahar EM, Brand H (1992) Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 121: 819–821PubMedGoogle Scholar
  87. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 10: 522–526PubMedGoogle Scholar
  88. Silver H, Geratsy N, Schwartz M (1995) No difference in the effect of biperiden and amantadine on parkinsonian and tardive dyskinesia-type involuntary movements: a double-blind, cross-over, placebo-controlled study in medicated chronic schizophrenia patients. J Clin Psychiatry 56: 167–170PubMedGoogle Scholar
  89. Snoey ER, Bessen HA (1990) Acute psychosis after amantadine overdose. Ann Emerg Med 19: 668–670PubMedGoogle Scholar
  90. Starr MS (1995) Antiparkinsonian action of glutamate antagonists — alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm [PD Sect] 10: 141–185Google Scholar
  91. Stewart JT (1987) Adverse behavioral effects of amantadine therapy in Huntington’s disease. South Med J 80: 1324–1325PubMedGoogle Scholar
  92. Stoof JC, Booij J, Drukarch B (1992) Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 94 [Suppl]: S4–S6PubMedGoogle Scholar
  93. Streifler M, Kallay V (1972) Amantadine in Parkinson’s disease. Harefuah 82: 499–502 (Hebrew with English Abstract)PubMedGoogle Scholar
  94. Streifler M, Hait Z (1973) Amantadinderivate bei Parkinsonismus im Blindversuch. Therapiewoche 40: 3549–3652Google Scholar
  95. Streifler M, Avrami E (1975) Levodopa and the secretion of sebum in parkinsonian patients. Eur Neurol 19: 43–48Google Scholar
  96. Taylor WA, Gold MS (1990) Pharmocologic approaches to the treatment of cocaine dependence. West J Med 152: 573–577PubMedGoogle Scholar
  97. Tennant FS, Sagherian AA (1987) Double blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocainie dependence. Arch Int Med 147: 109–112Google Scholar
  98. Thompson DF (1992) Amantadine in the treatment of cocaine withdrawal. Ann Pharmacother 26: 933–934PubMedGoogle Scholar
  99. Toru M, Matsuda D, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome — like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169: 324–327PubMedGoogle Scholar
  100. Turski L (1991) Excitatory amino acid antagonists and Parkinson’s disease. In: Rinne UK, Nagatsaku T, Horowski R (eds) International Workshop Berlin — Parkinson’s disease. Bussum (Netherlands) Medicom, pp 97–112Google Scholar
  101. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1995) Improved survival in Parkinson’s disease with use of amantadine. J Neural Transm [Gen Sect] 102: XLIX (Abstract)Google Scholar
  102. van Reekum R, Bayley M, Garner S, Burke JM, Fawcett S, Hart A, Thompson W (1995) Amantadine for the a-motivational syndrome in a patient with traumatic brain injury. Brain Inj 9: 49–53PubMedGoogle Scholar
  103. Vardi J, Streifler M (1975) On the synchronizing effect of amantadine-1-hydrochloride (Symmetrel) on pathological EEG activity. J Neural Transm 37: 73–80PubMedGoogle Scholar
  104. Warner JD (1985) Amantadine in chronic granulomatous disease (letter). Lancet ii: 1024–1027Google Scholar
  105. Weddington WW Jr, Brown BS, Haertzen CA, Hess JM, Mahaffey JB, Kolar AF, Jaffe JH (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug-Alcohol-Abuse 17: 137–152PubMedGoogle Scholar
  106. Weller M, Kornhuber J (1992) A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 38: 329–333PubMedGoogle Scholar
  107. Weller M, Kornhuber J (1993) Amantadine withdrawal and neuroleptic malignant syndrome. Neurology 43: 2155PubMedGoogle Scholar
  108. Wilcox JA, Tsuang J (1990) Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 23: 144–146PubMedGoogle Scholar
  109. Winkler A (1973) Die Behandlung herpetischer Dermatosen mit einem neuartigen Virustaticum. Med Welt 24: 1024–1027PubMedGoogle Scholar
  110. Woo J, Teoh R, Vallance-Owen J (1986) Neuroleptic malignant syndrome successfully treated with amantadine. Postgrad Med J 62: 809–810PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • J. Kornhuber
  • J. Wiltfang
  • M. Streifler

There are no affiliations available

Personalised recommendations